TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

3.10$ +4.7% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Prime Medicine, Inc. (PRME) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1.2 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement PRME
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
0.0 26 0.6 38 0.2 2.2 1.5 1.1 1.2 0.8 0.9 1.2 4.1
4.4 1.2 1.3 1.5 1.6 1.7 1.7 1.9 44 1.9 1.9
-4.4 -1.2 -0.7 -1.5 0.2 2.2 1.5 -0.7 -43 0.8 -1.0 1.2 -42
41 41 38 43 40 34 41 41 44 35 34 33 146
10 13 11 13 14 12 13 13 11 15 17 11 54
51 68 48 56 54 46 54 53 11 49 50 44 155
-51 -68 -48 -56 -54 -44 -52 -53 -54 -49 -51 -43 -197
0.4
-51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49 -42 -188
-0.1 0.6 0.1 -0.1
-51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49 -42 -188
-50 -53 -44 -54 -51 -41 -50 -51 -49 -44 -47 -40 -180

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?